What is the 13F Pro Quality Score for CLPT?

13F Pro ranks ClearPoint Neuro, Inc. (CLPT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CLPT's current score at https://13fpro.ai/research/CLPT (free sign-up required for the full ranking).

Which hedge funds own the most CLPT stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CLPT include BlackRock,, MAK CAPITAL ONE, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CLPT as soon as new 13F filings post.

Where does 13F Pro source CLPT data?

All ClearPoint Neuro, Inc. fundamentals and ownership data come directly from SEC EDGAR. ClearPoint Neuro, Inc. files with the SEC under CIK 1285550. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CLPT in?

ClearPoint Neuro, Inc. (CLPT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CLPT research updated on 13F Pro?

CLPT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ClearPoint Neuro, Inc.(CLPT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1285550 CLPT stock profile & AI dashboard →

13F Pro Quality Score

28.8/100

Rank #2,429 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

84.6/100

Profitability

8.5/100

Balance Sheet

8.0/100

Earnings Quality

30.0/100

Free Cash Flow

9.0/100

Institutional Flow

86.7/100

Revenue Scale

9.0/100

Dilution Risk

8.4/100

CLPT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ClearPoint Neuro, Inc. (CLPT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CLPT at 28.8/100 on a 32-signal composite quality model, placing it at rank #2,429 of 2,879 stocks — the bottom half of the AI-ranked universe. CLPT scores in the top quartile across institutional flow (86.7), revenue growth (84.6). Areas of concern include balance sheet strength (8.0) and profitability (8.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ClearPoint Neuro, Inc. reports quarterly revenue of $12.1M, net income of $-9.6M, an operating margin of -69.9%. Top institutional holders of CLPT by reported 13-F value include BlackRock,, MAK CAPITAL ONE, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CLPT trades on the Nasdaq exchange and files with the SEC under CIK 1285550. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLPT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ClearPoint Neuro, Inc. directly from SEC EDGAR. ClearPoint Neuro, Inc.'s 13F Pro composite quality score has ranged between 25 and 29 since 2025, currently 28.8 — an improving long-term trajectory across 12 quarterly and live scoring snapshots.

Revenue

Q1 2026

$12.1M

Net Income

Q1 2026

$-9.6M

Free Cash Flow

Q1 2026

$-8.6M

Operating Margin

Q1 2026

-69.9%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+17.8% YoY

$37.0MFY 2025

FY22 $20.6MFY23 $24.0MFY24 $31.4MFY25 $37.0M

Net Income

-35.0% YoY

$-25.5MFY 2025

FY22 $-16.4MFY23 $-22.1MFY24 $-18.9MFY25 $-25.5M

Operating Income

-22.4% YoY

$-24.2MFY 2025

FY22 $-16.3MFY23 $-22.4MFY24 $-19.7MFY25 $-24.2M

EPS (Diluted)

-28.6% YoY

$-0.90FY 2025

FY22 $-0.68FY23 $-0.90FY24 $-0.70FY25 $-0.90

Total Assets

+149.4% YoY

$97.7MFY 2025

FY22 $55.5MFY23 $42.7MFY24 $39.2MFY25 $97.7M

Total Debt

$49.1MFY 2025

FY22 $9.9MFY23 $9.9MFY24 —FY25 $49.1M

Op. Cash Flow

-165.6% YoY

$-23.9MFY 2025

FY22 $-16.2MFY23 $-13.7MFY24 $-9.0MFY25 $-23.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$37.0M +17.8%	$31.4M +31.0%	$24.0M +16.6%	$20.6M +26.1%	$16.3M +27.0%	$12.8M
Net Income	$-25.5M -35.0%	$-18.9M +14.4%	$-22.1M -34.4%	$-16.4M -14.1%	$-14.4M -112.5%	$-6.8M
Operating Income	$-24.2M -22.4%	$-19.7M +12.1%	$-22.4M -37.4%	$-16.3M -22.1%	$-13.4M -115.0%	$-6.2M
EPS (Diluted)	$-0.90 -28.6%	$-0.70 +22.2%	$-0.90 -32.4%	$-0.68 +1.4%	$-0.69	—
Total Assets	$97.7M +149.4%	$39.2M -8.1%	$42.7M -23.1%	$55.5M -15.4%	$65.6M +122.2%	$29.5M
Total Debt	$49.1M	—	$9.9M +0.6%	$9.9M +0.6%	$9.8M -53.8%	$21.3M
Operating Cash Flow	$-23.9M -165.6%	$-9.0M +34.3%	$-13.7M +15.3%	$-16.2M -27.3%	$-12.7M -62.7%	$-7.8M

AI Insight: CLPT Financial Trends

Revenue inflection to $12M in Q1 2026 masks deteriorating unit economics and sharply rising leverage.

• Revenue grew 50% from $8M in Q2 2024 to $12M in Q1 2026, first sustained sequential growth.

• Operating losses widened from $5M in Q2 2024 to $8M in Q1 2026 despite revenue gains.

• Total debt surged from $10M in Q2 2024 to $50M in Q1 2026; equity declined 41% to $19M.

⚠ Operating cash flow deteriorated sharply to negative $8M in Q1 2026, worst quarter on record.

⚠ Net losses accelerated to $10M in Q1 2026 despite revenue growth—unsustainable burn trajectory.

AI Insight: CLPT Ratio Trends

ClearPoint Neuro remains deeply unprofitable with deteriorating unit economics and rising leverage in Q1 2026.

• Operating margin worsened to -69.9% in Q1 2026 from -67.7% in Q4 2025; net margin collapsed to -78.8%.

• ROIC fell to -49.5% in Q1 2026 from -36.5% in Q4 2025, extending a multi-quarter trend of negative returns.

• Debt-to-equity ratio rose to 2.63 in Q1 2026 from 1.75 in Q4 2025, reaching the highest level since TTM data began.

⚠ ROA deteriorated to -40.9% in Q1 2026, worsening from -31.9% in Q4 2025. Asset efficiency is eroding.

⚠ Consistent negative profitability across all margin metrics suggests operational cash burn persists without revenue inflection.

Get alerted when CLPT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ClearPoint Neuro, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CLPT

BlackRock, Inc.
$19.0M2,082,750 sh
MAK CAPITAL ONE LLC
$17.3M1,901,489 sh
VANGUARD CAPITAL MANAGEMENT LLC
$11.3M1,243,615 sh
GEODE CAPITAL MANAGEMENT, LLC
$6.4M705,720 sh
STATE STREET CORP
$6.2M679,819 sh
Lane Generational LLC
$4.4M486,849 sh
GOLDMAN SACHS GROUP INC
$4.2M463,617 sh
UBS Group AG
$3.9M432,360 sh
BROWN ADVISORY INC
$3.0M325,906 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.6M284,809 sh

Fund	Value	Shares
BlackRock, Inc.	$19.0M	2,082,750
MAK CAPITAL ONE LLC	$17.3M	1,901,489
VANGUARD CAPITAL MANAGEMENT LLC	$11.3M	1,243,615
GEODE CAPITAL MANAGEMENT, LLC	$6.4M	705,720
STATE STREET CORP	$6.2M	679,819
Lane Generational LLC	$4.4M	486,849
GOLDMAN SACHS GROUP INC	$4.2M	463,617
UBS Group AG	$3.9M	432,360
BROWN ADVISORY INC	$3.0M	325,906
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.6M	284,809

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CLPT on your watchlist

Track score changes the day ClearPoint Neuro, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CLPT a good stock to buy?

13F Pro's AI-powered analysis of ClearPoint Neuro, Inc. (CLPT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CLPT are available on the CLPT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CLPT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CLPT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ClearPoint Neuro, Inc.'s investment landscape.